Arcus Biosciences, Inc. (RCUS) Scorecard
- 2026-Q2: Total return Win; Revenue growth Win; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth Lose; EPS growth Lose.
32/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 4 wins, 8 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q22/3 |
WinRCUS / S&P 42.73% / 15.20% |
WinRCUS / S&P 23.91% / 15.00% |
LoseRCUS / S&P 23.34% / 50.40% |
| 2026-Q10/3 |
LoseRCUS / S&P -9.36% / -4.33% |
LoseRCUS / S&P -34.69% / 11.30% |
LoseRCUS / S&P -23.87% / 27.70% |
| 2025-Q41/3 |
WinRCUS / S&P 75.22% / 2.65% |
LoseRCUS / S&P -35.29% / 9.00% |
LoseRCUS / S&P 6.77% / 13.40% |
| 2025-Q31/3 |
WinRCUS / S&P 67.08% / 8.12% |
LoseRCUS / S&P -314.29% / 4.61% |
LoseRCUS / S&P 9.21% / 13.45% |
| 2025-Q21/3 |
LoseRCUS / S&P 3.69% / 10.94% |
WinRCUS / S&P 1050.00% / 4.83% |
LoseRCUS / S&P 2.59% / 10.63% |
| 2025-Q12/3 |
LoseRCUS / S&P -47.28% / -4.27% |
WinRCUS / S&P 122.73% / 4.98% |
WinRCUS / S&P 34.73% / 10.57% |
| 2024-Q41/3 |
LoseRCUS / S&P -2.62% / 2.41% |
WinRCUS / S&P 37.84% / 5.25% |
LoseRCUS / S&P -25.30% / 6.15% |
| 2024-Q30/3 |
LoseRCUS / S&P 0.39% / 5.89% |
LoseRCUS / S&P -145.65% / 5.89% |
LoseRCUS / S&P -21.25% / 6.11% |
| 2024-Q20/3 |
LoseRCUS / S&P -19.33% / 4.28% |
LoseRCUS / S&P -91.49% / 5.38% |
LoseRCUS / S&P -21.97% / 5.12% |
| 2024-Q10/3 |
LoseRCUS / S&P -1.15% / 10.56% |
LoseRCUS / S&P -51.11% / 5.71% |
LoseRCUS / S&P RCUS unavailable / 5.59% |
| 2023-Q40/3 |
LoseRCUS / S&P 6.41% / 11.69% |
LoseRCUS / S&P -2.63% / 6.81% |
LoseRCUS / S&P RCUS unavailable / 7.78% |
| 2023-Q30/3 |
LoseRCUS / S&P -11.62% / -3.27% |
LoseRCUS / S&P -89.37% / 7.52% |
LoseRCUS / S&P RCUS unavailable / -5.03% |
| 2023-Q21/3 |
WinRCUS / S&P 11.35% / 8.74% |
LoseRCUS / S&P -88.51% / 9.50% |
LoseRCUS / S&P RCUS unavailable / -8.57% |
| 2023-Q10/3 |
LoseRCUS / S&P -11.80% / 7.50% |
LoseRCUS / S&P -88.51% / 10.77% |
LoseRCUS / S&P RCUS unavailable / -15.69% |
| 2022-Q40/3 |
LoseRCUS / S&P -20.95% / 7.56% |
LoseRCUS / S&P -90.08% / 11.88% |
LoseRCUS / S&P RCUS unavailable / -17.99% |
| 2022-Q32/3 |
WinRCUS / S&P 3.24% / -4.88% |
WinRCUS / S&P 1027.99% / 13.47% |
LoseRCUS / S&P RCUS unavailable / -1.41% |
| 2022-Q21/3 |
LoseRCUS / S&P -19.71% / -16.10% |
WinRCUS / S&P 337.88% / 13.71% |
LoseRCUS / S&P RCUS unavailable / 11.04% |
| 2022-Q11/3 |
LoseRCUS / S&P -22.02% / -4.60% |
WinRCUS / S&P 356.81% / 15.97% |
LoseRCUS / S&P RCUS unavailable / 42.23% |
| 2021-Q42/3 |
WinRCUS / S&P 16.06% / 11.03% |
WinRCUS / S&P 391.03% / 15.00% |
LoseRCUS / S&P RCUS unavailable / 96.40% |
| 2021-Q31/3 |
WinRCUS / S&P 26.98% / 0.58% |
LoseRCUS / S&P -50.69% / 10.77% |
LoseRCUS / S&P RCUS unavailable / 69.42% |
| 2021-Q21/3 |
LoseRCUS / S&P -2.21% / 8.55% |
WinRCUS / S&P 522.81% / 6.58% |
LoseRCUS / S&P RCUS unavailable / 51.81% |
| 2021-Q12/3 |
WinRCUS / S&P 8.17% / 6.17% |
WinRCUS / S&P 471.41% / -1.06% |
LoseRCUS / S&P RCUS unavailable / 7.39% |
| 2020-Q42/3 |
WinRCUS / S&P 51.46% / 12.15% |
WinRCUS / S&P 420.00% / -3.72% |
LoseRCUS / S&P RCUS unavailable / -33.42% |
| 2020-Q31/3 |
LoseRCUS / S&P -30.72% / 8.93% |
WinRCUS / S&P 1041.81% / -2.04% |
LoseRCUS / S&P RCUS unavailable / -27.10% |
| 2020-Q22/3 |
WinRCUS / S&P 78.24% / 20.54% |
WinRCUS / S&P 60.38% / -0.46% |
LoseRCUS / S&P RCUS unavailable / -27.11% |
| 2020-Q12/3 |
WinRCUS / S&P 37.43% / -19.60% |
WinRCUS / S&P 69.43% / 3.47% |
LoseRCUS / S&P RCUS unavailable / -14.75% |
| 2019-Q42/3 |
WinRCUS / S&P 10.99% / 9.07% |
WinRCUS / S&P 79.58% / 5.36% |
LoseRCUS / S&P RCUS unavailable / 2.99% |
| 2019-Q31/3 |
WinRCUS / S&P 14.47% / 1.70% |
LoseRCUS / S&P -15.28% / 5.02% |
LoseRCUS / S&P RCUS unavailable / 0.21% |
| 2019-Q21/3 |
LoseRCUS / S&P -36.35% / 4.30% |
WinRCUS / S&P 139.02% / 6.64% |
LoseRCUS / S&P RCUS unavailable / 8.65% |
| 2019-Q11/3 |
WinRCUS / S&P 15.97% / 13.65% |
LoseRCUS / S&P RCUS unavailable / 8.12% |
LoseRCUS / S&P RCUS unavailable / 14.29% |
| 2018-Q40/3 |
LoseRCUS / S&P -22.74% / -13.52% |
LoseRCUS / S&P RCUS unavailable / 9.05% |
LoseRCUS / S&P RCUS unavailable / 18.23% |
| 2018-Q31/3 |
WinRCUS / S&P 13.89% / 7.71% |
LoseRCUS / S&P RCUS unavailable / 10.21% |
LoseRCUS / S&P RCUS unavailable / 19.06% |
| 2018-Q20/3 |
LoseRCUS / S&P -20.73% / 3.43% |
LoseRCUS / S&P RCUS unavailable / 9.03% |
LoseRCUS / S&P RCUS unavailable / 14.46% |
| 2018-Q10/3 |
LoseRCUS / S&P RCUS unavailable / -0.76% |
LoseRCUS / S&P RCUS unavailable / 7.68% |
LoseRCUS / S&P RCUS unavailable / 12.46% |
| 2017-Q40/3 |
LoseRCUS / S&P RCUS unavailable / 6.64% |
LoseRCUS / S&P RCUS unavailable / 7.03% |
LoseRCUS / S&P RCUS unavailable / 13.82% |
| 2017-Q30/3 |
LoseRCUS / S&P RCUS unavailable / 4.48% |
LoseRCUS / S&P RCUS unavailable / 5.68% |
LoseRCUS / S&P RCUS unavailable / 17.57% |
| 2017-Q20/3 |
LoseRCUS / S&P RCUS unavailable / 3.09% |
LoseRCUS / S&P RCUS unavailable / 4.83% |
LoseRCUS / S&P RCUS unavailable / 17.74% |
| 2017-Q10/3 |
LoseRCUS / S&P RCUS unavailable / 6.07% |
LoseRCUS / S&P RCUS unavailable / 3.67% |
LoseRCUS / S&P RCUS unavailable / 13.32% |
| 2016-Q40/3 |
LoseRCUS / S&P RCUS unavailable / 3.82% |
LoseRCUS / S&P RCUS unavailable / 2.09% |
LoseRCUS / S&P RCUS unavailable / 7.05% |
| 2016-Q30/3 |
LoseRCUS / S&P RCUS unavailable / 3.85% |
LoseRCUS / S&P RCUS unavailable / 0.20% |
LoseRCUS / S&P RCUS unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | RCUS total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 188.86% | 20.78% |
| Annualized return | 188.86% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | RCUS total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -3.04% | 83.14% |
| Annualized return | -0.62% | 12.86% |
10Y · 2018-03-15 to 2026-08-27
| Metric | RCUS total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 79.94% | 319.30% |
| Annualized return | 6.05% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |